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Amazon – a qualitative study exploring the
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and healthcare professionals
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Abstract
Background: Management for multi-drug-resistant tuberculosis (MDR-TB) is challenging and has poor patient outcomes.
Peru has a high burden of MDR-TB. The Loreto region in the Peruvian Amazon is worst affected for reasons including
high rates of poverty and poor healthcare access. Current evidence identifies factors that influence MDR-TB medication
adherence, but there is limited understanding of the patient and healthcare professional (HCP) perspective, the HCP-
patient relationship and other factors that influence outcomes. A qualitative investigation was conducted to explore and
compare the experiences and perceptions of MDR-TB patients and their dedicated HCPs to inform future management
strategies.
Method: Twenty-six, semi-structured in-depth interviews were conducted with 15 MDR-TB patients and 11 HCPs who
were purposively recruited from 4 of the worst affected districts of Iquitos (capital of the Loreto region). Field notes and
transcripts of the two groups were analysed separately using thematic content analysis. Ethics approval was received from
the Institutional Research Ethics Committee, Department of Health, Loreto, and the University of Birmingham Internal
Research Ethics Committee.
Results: Four key themes influencing patient outcomes emerged in each participant group: personal patient factors,
external factors, clinical factors, and the HCP-patient relationship. Personal factors included high standard patient and
population knowledge and education, which can facilitate engagement with treatment by encouraging belief in
evidence-based medicine, dispelling belief in natural medicines, health myths and stigma. External factors included the
adverse effect of the financial impact of MDR-TB on patients and their families. An open, trusting and strong HCP-patient
relationship emerged as a vitally important clinical factor influencing of patient outcomes. The results also provide
valuable insight into the dynamic of the relationship and ways in which a good relationship can be fostered.
Conclusions: This study highlights the importance of financial support for patients, effective MDR-TB education and the
role of the HCP-patient relationship. These findings add to the existing evidence base and provide insight into care
improvements and policy changes that could improve outcomes if prioritised by local and national government.
Keywords: Multi-drug-resistant tuberculosis, Experiences, Perceptions, Healthcare professional, Patient, Relationship,
Qualitative, Outcomes, Peru
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Background
Tuberculosis (TB) remains one of the top 10 causes of
death globally, despite the availability of curative treat-
ment [1]. Multi-drug-resistant tuberculosis (MDR-TB)
accounts for a sizable proportion of TB and has rapidly
become a global public health crisis [2]. In 2016 there
were 10.4 million new cases of TB notified worldwide,
with 490,000 classified as multi-drug-resistant [2].
MDR-TB is defined as a strain exhibiting resistance to
isoniazid and rifampicin, two key first-line anti-TB drugs
[3]. Therefore, patients require varying regimens of sec-
ond-line therapies depending on their MDR-TB strain
sensitivities. These second-line therapies, which are
summarised in \ file 2, are less effective and cause more
side-effects, which are more disabling. Consequently, pa-
tient outcomes for MDR-TB are worse compared to
non-resistant strains. Poor treatment outcomes for
MDR-TB have far reaching medical and public health
implications, including higher rates of transmission in
the population [4–7].
More than 95% of deaths due to TB occur in low and
middle-income countries, including Peru. Peru retains
the highest incidence of TB amongst Latin American
countries, reaching 119 cases per 100,000 population per
year [8]. Of concern, Peru remains the only South
American country with a high-burden of MDR-TB,
which is responsible for 10% of all TB, with up to 40% of
MDR-TB patients receiving inappropriate therapies [1].
Mortality rates in some districts approach 20–55% [9, 10],
compared to 4.5–17% for drug-sensitive TB [11, 12]. The
incidence of MDR-TB in Loreto increased by 175% from
2013 to 2014. In 2014, 25% of patients left their treatment
program and 20% of MDR-TB patients died [13]. TB pre-
vention and treatment has improved in Peru [1, 14]. How-
ever, factors including inadequate public health strategies,
limited funding and low adherence to treatment have con-
tributed to high rates of resistance, especially in lower
income regions [15–17]. Loreto, which has poor health-
care access and poverty rates reaching 63%, compared to
21.7% in Lima [18], has the highest prevalence of MDR-
TB of all Peru regions, prompting local government to
identify MDR-TB as a research priority in 2015 [19].
A MEDLINE literature search using the terms “MDR-
TB” AND “Peru” AND “qualitative” revealed little quali-
tative investigation of MDR-TB management in Peru
[16, 17]. The role of nurses as providers of emotional
support to MDR-TB patients was explored in an inter-
view-based study in Lima [16]. Barriers to optimal out-
comes included poor adherence, quality of medical care
and patient knowledge, medication side-effects, social
stigma, socioeconomic factors, delayed presentation and
mistrust of TB medication. Facilitators included a pa-
tient-centred approach, community and family support,
a focus on psychosocial well-being through counselling
for the duration of treatment and patient feelings of au-
tonomy and control. Horter et al. added that hope of a
cure, high-quality knowledge, patients’ belief in treat-
ments and being involved in the decision-making
process improved adherence [20]. Conversely, a hier-
archical healthcare professional-patient relationship,
where patients felt unable to share concerns through
fear of judgment, adversely affected adherence [21].
More aggressive treatment regimens with more drugs at
higher doses have been shown to reduce all-cause mor-
tality for MDR-TB patients [22]. Good patient education
has improved outcomes by helping to allay mistaken
health beliefs and myths [23, 24] and promote patient
belief in their ability to be cured [5, 25–27]. In a system-
atic review investigating adherence to TB treatment,
Munro et al. stressed the importance of personal factors,
for example knowledge and motivation, as well as struc-
tural factors beyond the control of the patient including
poverty, accessibility of care and the organisation of the
local, regional and national government MDR-TB strat-
egies [23]. Patients with comorbidities, for example HIV
or diabetes mellitus, also demonstrate worse outcomes
with MDR-TB [28, 29]. The financial impact of MDR-
TB on patients is also an important barrier to successful
treatment, especially in Peru [16, 25, 30–32]. MDR-TB
patients are subject to extreme financial and employ-
ment hardship. A 2014 study investigating the financial
impact of MDR-TB on patients and their families re-
vealed that the majority of patients have to leave their
job, move house and sell their possessions in order to af-
ford accessing their treatment [25].
While current evidence identifies factors that influence
adherence to treatment, there is limited understanding
of the patient perspective on MDR-TB treatment and
other factors that influence patient outcomes. The per-
ceptions of patients have also not been compared to
those of HCPs, which could provide a valuable insight
into the dynamic of the HCP-patient relationship.
Research to date into MDR-TB in Peru is limited to
Lima, which has a differing socio-demographic profile,
dissimilar cultural attitudes and increased healthcare
funding, and may not be generalisable to other regions
[19]. In order to halt the MDR-TB epidemic in Loreto,
research into patient and HCP experiences and percep-
tions in the region is needed. This study aims to explore
the experiences and perceptions of MDR-TB patients
and HCPs in Loreto in order to identify barriers and fa-
cilitators to achieving optimal outcomes and to help in-
form future management strategies.
Methods
A qualitative study was undertaken to improve under-
standing of barriers and facilitators to achieving optimal
outcomes by investigating the perceptions, experiences
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and beliefs of patients and their dedicated HCPs regard-
ing MDR-TB [33]. Semi-structured interviews were con-
ducted with MDR-TB patients and HCPs between
January and March 2018.
Setting
The study location was Iquitos, capital of the Loreto re-
gion of the Peruvian Amazon. It is the largest urban area
in Loreto with an estimated 2016 population of 437,000
[34]. Participants were recruited from the San Juan,
Moronacocha, Belen and Nanay districts, areas with high
rates of MDR-TB.
Population and sampling criteria
Interviews were conducted with patients (past or
present) and HCPs attending or working at primary
healthcare centres in the 4 districts above.
Purposive sampling was used to achieve maximum
variation in response and explore emerging themes fol-
lowing interim analyses [35], while providing a balance
of HCPs and patients for comparative purposes. Patient
participants were recruited to facilitate variation in per-
spectives across education status, occupation, age, gen-
der and socioeconomic status. Patients were excluded if
younger than 18 years, unable to speak Spanish or
English fluently, lacking capacity to give informed con-
sent or suffering from another illness which could affect
their ability to conduct a meaningful interview or cause
harm or stress. HCPs were purposively recruited to in-
clude different clinics and professions. Participants were
recruited in both groups until data saturation was
reached [36].
Recruitment
Patient and HCP participants were approached by the
principal investigator (TM) and given written informa-
tion about the study. Potential participants who were
prepared to proceed gave informed written consent.
Interviews were arranged at a time and location con-
venient for the participant. For patients, these were
undertaken either in a private room at their health
centre or in their home. For staff, interviews were in
their place of work.
Data collection
Semi-structured, face-to-face interviews were carried out
to allow participants to express their views without being
influenced or inhibited by others [37]. Interviews exam-
ined participants’ perceptions, beliefs and experiences of
MDR-TB and their views on factors that influence
patient outcomes both positively and negatively. The
exploratory nature of the research question called for an
open approach to questioning since the aim was gener-
ation of new theory.
All interviews were carried out in Spanish, with the
help of a translator. TM asked questions in English,
the translator translated them into Spanish for the
participant and then translated the participants’ re-
sponses into English for TM. Prior to the first inter-
view, the translator signed a confidentiality agreement.
The information sheet, consent form, demographic
questionnaire and topic guide (Additional file 1) were
translated into Spanish before data collection began and
reviewed by the translator to ensure clarity and
comprehensibility.
A topic guide was used for all interviews, which ensured
that all important areas were discussed while allowing the
participant to lead the conversation to subjects important
to them [38]. The topic guide covered factors already
shown to influence MDR-TB patient outcomes, while en-
couraging the participants to discuss ideas not represented
in the literature. The topic guide was piloted on Day 1 and
modified to improve clarity and acceptability of the ques-
tions and prevent interview misdirection [39, 40]. The
quality of the translation was checked using a transcrip-
tion of the pilot interview and the audio recording.
The average interview duration was 32min (range 20–
50min). This limited the demand on participants while
allowing them to explore factors in as much detail as they
wished. All interviews were audio-recorded after consent.
Immediately after each interview TM recorded field notes,
observations and reflections to increase the accountability
and trustworthiness of the findings [40]. TM interacted
only as a researcher and not as a clinician in order to
maintain independence and to reduce study bias.
Data analysis
TM transcribed the English components of the interview
audio-recordings and field notes within 24 h of the inter-
view. Spanish parts of the conversation were transcribed
by the translator. The accuracy of the translation was
checked for 50% of transcriptions to ensure data validity
and discrepancies were rectified by discussion.
Thematic content analysis was most appropriate for
this study design to provide a rich understanding of per-
ceptions, beliefs and experiences [41]. Themes were
developed and refined using the 6-step approach pro-
posed by Braun and Clarke [41].
Data analysis occurred alongside data collection in an
iterative process to inform sampling for future interviews
and to assess data saturation. Constant comparison of
codes and theory from interim analyses within and be-
tween interviews helped to test and generate new theory
[41]. Analytical memos were kept to track the develop-
ment of theory and to ensure transparency. Analytical
triangulation was carried out with CI who independently
analysed transcripts. Discrepancies were resolved via dis-
cussion. Transcripts were read and re-read to actively
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search for discrepancies within the data, contradictory
or unexpected findings and to ensure that findings were
a true reflection of the data and participant voice [33].
Ethical considerations
The study was approved by the Institutional Research
Ethics Committee, Department of Health, Loreto on the
8th January 2018 and The University of Birmingham
Internal Research Ethics Committee on the 12th January
2018. Data were stored according to University of
Birmingham data protection policy [42].
Results
Twenty patients with MDR-TB were identified from
local registers for recruitment. Five could not be traced.
No participants were excluded on the basis of language.
Of 15 patients interviewed 14 had confirmed MDR-TB
of whom 12 were receiving active treatment and 2 had
been successfully treated. Data from one patient inter-
view (participant 023) was excluded from the final ana-
lysis when a review of the records revealed they had
mono-resistant TB. The age range of patients was 19 to
71 years, with 10 males and 4 females. Table 1 summa-
rises the demographic data of patient participants.
Eleven HCPs were recruited including 8 dedicated TB
nurses and 3 TB physicians. Table 2 summarises the demo-
graphic data of HCP participants. Twenty-six interviews
were conducted in Spanish by TM and the translator.
Separate analyses of the two groups generated 4 iden-
tical key themes: 1) personal patient factors; 2) external
factors; 3) clinical factors; and 4) HCP-patient relation-
ship. Patient and HCP themes and subthemes are
summarised in Tables 3 and 4 respectively. Since sam-
pling was purposive, the numbers of respondents ex-
pressing certain views indicate whether a theme was
rarely or commonly expressed, rather than indicating
importance. Where appropriate, quotes from both par-
ticipant groups have been paired to illustrate similarity
or difference in perception between groups.
Personal patient factors affecting outcomes
This theme explores patient contributed factors that can
influence outcomes of MDR-TB treatment including
patient knowledge, beliefs about or attitude towards
MDR-TB and its treatment.
Poor patient knowledge and information
Ten patients exhibited limited knowledge and under-
standing of MDR-TB with a proportion of patients un-
able to offer even a simple description of the disease:
Researcher: What do you understand about
tuberculosis as a disease?
Well, I can’t really tell you anything about it. (025 -
patient)
I don’t know how to explain what causes it because I
don’t know how I got it. 004 (patient).
Resistance is a difficult concept and only 4 patients
were able to explain the term correctly. Most patients
understood MDR-TB as “stronger” or “harder to cure”.
This finding was echoed in interviews with HCPs who
described a limited level of understanding of MDR-TB
in the general population:
Table 1 Summary of demographic characteristics of patient
participants
Group (participant number) Age Address Education
Patient – 1 (002) 25–34 Belen University
Patient – 2 (003) 18–24 San Juan University
Patient – 3 (004) 65–74 San Juan Primary
Patient – 4 (006) 55–64 Moronacocha University
Patient – 5 (007) 55–64 Belen Secondary
Patient – 6 (009) 18–24 San Juan Secondary
Patient – 7 (010) 35–44 Belen Secondary
Patient – 8 (013) 25–34 San Juan Secondary
Patient – 9 (015) 18–24 Nanay Secondary
Patient – 10 (018) 45–54 Nanay Secondary
Patient – 11 (019) 45–54 Moronacocha Secondary
Patient – 12 (022) 55–64 Moronacocha Secondary
Patient – 13 (025) 45–54 Nanay Primary
Patient – 14 (026) 55–64 Moronacocha Secondary
Table 2 Summary of demographic characteristics of HCP
participants
Group
(participant number)
Age Address Education
HCP – 1 (001) 25–34 Iquitos University
HCP – 2 (005) 35–44 Belen Other
(Nurse apprenticeship)
HCP – 3 (008) 35–44 San Juan University
HCP – 4 (011) 25–34 Iquitos University
HCP – 5 (012) 35–44 San Juan University
HCP – 6 (014) 25–34 Iquitos University
HCP – 7 (016) 45–54 Iquitos Other –
(Nurse apprenticeship)
HCP – 8 (017) 45–54 San Juan Bautista University
HCP – 9 (020) 55–64 Iquitos University
HCP – 10 (021) 25–34 San Juan University
HCP – 11 (024) 35–44 Punchana Other
(Nurse apprenticeship)
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[The] nurse gives the patients who come to the health
centre enough information about the symptoms … If
they don’t come, they don’t develop a good
understanding. (017 - HCP)
Some patients blamed their poor level of knowledge
on inadequate education from HCPs:
Some of them explain to you, but some of them don’t. I
don’t know very much about this illness. (013 - patient)
Most patients showing poor knowledge saw educa-
tion as the responsibility of HCPs and did not ac-
tively seek out information about their illness.
Patients who exhibited a good level of understanding
saw education as their responsibility and actively
sought information from a number of sources, par-
ticularly the internet:
When I came here, and the doctors gave me the diagnosis,
they didn’t tell me about the illness and what I could do
… And in my case, I searched the internet. That’s why I
know what this illness is about. (003 - patient)
Good patient knowledge and education
Despite gaps in some areas of knowledge, 10 patients
mentioned the importance of adherence to the end of
the treatment schedule. Furthermore, HCPs indicated
that often patients suspected they had TB prior to their
diagnosis, indicating a prior knowledge of symptoms and
disease progression:
When you tell patients that they have tuberculosis,
usually they already know about it … They usually
say, “I guessed I had that, I thought it was
tuberculosis”. (001 - HCP)
The importance of high standard education and patient
understanding was stressed by 10 HCPs and 6 considered
it among the most important factors for achieving optimal
outcomes. HCPs described quality education as establish-
ing knowledge of TB and MDR-TB transmission, the ne-
cessity of adherence and consequences of poor adherence,
side-effects and of the efficacy of pharmaceutical medica-
tions. Through developing a good understanding, patients
are more accepting of side-effects and are more optimistic
about their outcome:
Table 3 Themes and subthemes from patient interviews and patients’ views of their influence on MDR-TB outcomes. (Brackets
indicate the number of patients highlighting a subtheme in their interview, bold text indicates alignment of opinion between
patients and HCPs)
Theme Facilitators to achieving optimal outcomes (frequency out of 14) Barriers to achieving optimal outcomes (frequency out of 14)
Personal Factors − High standard patient knowledge, understanding
of resistance and of the importance of adherence to
the end of the treatment schedule (10)
− Education from a number of sources including the HCP,
peers and internet (8)
− Perception of MDR-TB as a dangerous and contagious illness (11)
− Belief in pharmaceutical medications (9)
− Positive perception of the future and hope in a cure (10)
− Positive patient attitude and a strong desire to be cured (7)
− Psychological resilience (11)
− Poor quality or limited knowledge (10)
− Contradictory advice/education from peers/
family/HCPs (10)
− Belief in natural medicines more than/as much
as pharmaceutical medications (7)
− Disbelief/distrust of pharmaceutical medications (11)
− Myths and misinformation (10)
− Negative patient attitude (6)
− Change in patient identity, not feeling “normal” (9)
− Experience/fear of stigma or discrimination (11)
− Psychological impact of MDR-TB (12)
− Isolation (11)
− Other comorbidities (4)
External Factors − Family support (emotional/psychological
/nutritional/financial) (11)
− Family willing to make sacrifices to help patient (8)
− Education of family to empower them to help patient (9)
− Religion as a source of psychological support (6)
− Holistic care provided by HCP team (10)
− Individualised care, patient feeling involved in
treatment planning (9)
− Pragmatic approach to providing high standard care
in a resource poor setting (5)
− Socioeconomic impact of illness and treatment (14)
− Poor nutrition (10)
− Resource poor health system (7)
− Lack of political will to tackle MDR-TB/TB on a
regional/country level (6)
− Impact of illness on family (socially/psychologically/
financially) (12)
− Disorganised care (7)
− Difficulty accessing treatment (8)
Clinical Factors − Feeling mentally and physically prepared for the treatment (9)
− Strategies to reduce nausea due to treatment (10)
− Diagnosis at late stage of disease (7)
− Side-effects of the treatment (14)
− Long duration of treatment (11)
HCP-patient
Relationship
(13)
− Good, open and trusting HCP-patient relationship (13)
− Patient feeling comfortable sharing worries
and concerns with HCPs without fearing judgment (12)
− Patient feeling valued (11)
− Good communication with HCP (12)
− Patient fear/experience of stigmatisation/
discrimination from HCPs (5)
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It is very important because depending on the
education we give to all patients and their families;
they will successfully follow the treatment. (008 - HCP)
We try to explain to them that if they have
tuberculosis they can only be cured if they follow the
treatment. (005 - HCP)
HCPs also stressed the importance of the method of
delivery and source of the information. Four HCPs de-
scribed using simple language to ensure patients could
grasp the difficult concepts:
I try to explain it in simple language, so they can
understand what they have … Sometimes they are
not able to understand clearly because we use …
some technical words related to medicine. (014 -
HCP)
HCPs emphasised the importance of educating the
population as a whole, while patients spoke mainly of edu-
cation of individuals and their families. Both groups, how-
ever, agreed that education of families was important to
enable them to support the patient more effectively:
We try to explain the illness and to educate the
family, too. We explain things related to this illness, so
the patient can feel in a good environment with their
family and … in their home. (011 - HCP)
Yes, it’s very very important [education of the
population]. We need to go to schools and educate the
whole population. (014 - HCP)
Schools were frequently mentioned as good locations
to educate the population about MDR-TB. In addition,
both HCPs and patients mentioned the internet as a
good source of information:
When I found out I had this illness, I searched the
internet for information about it … At the beginning I
thought this illness was like dengue or malaria, but …
now I am well informed. (003 - patient)
Patient health beliefs and alternative medicine
An initial distrust of medical advice and pharmaceutical
medicines was evident in 11 patient interviews, while
HCPs admitted difficulty explaining the efficacy of
pharmaceutical over natural medicines. This initial dis-
trust stemmed from strong cultural beliefs in natural
medicines and shamans, who are natural healers in the
Amazon region:
The belief of the whole population here is that first, if
they have an illness, they must go to see a shaman and
then after that they come to the health centre. (017 -
HCP (doctor))
Well, we are in Peru, aren’t we? … Here we have a
huge variety of natural medicines … I learnt about
natural medicines thanks to my grandmother… When
they didn’t have the opportunity to go to a health
centre or a hospital, they used to cure illnesses using
natural medicines. (009 - patient)
Some patients justified their belief in natural medicines
by proposing that previous generations survived condi-
tions such as tuberculosis using just natural medicines,
so they should be able to as well. These cultural beliefs
are compounded by contradictory advice from friends,
family and patients’ communities:
People tell me that, “you are going to die taking that
medication. You are going to be blind and you are
going to die.” (007 - patient)
While it is true that some MDR-TB medications, such as
ethambutol, can cause optic neuropathy and blindness, pa-
tients must tolerate these side-effects in order to rid their
body of MDR-TB. It was evident in some interviews that
patients and families incorrectly associated medication
side-effects with the patient’s overall condition worsening:
They [my family] tell me, for example … that I
shouldn’t take the pills from the health centre here.
They tell me that it’s better to take natural medicines.
(010 - patient)
Four patients revealed a belief that natural medicines
were “natural” and therefore safer and more effective
than pharmaceutical medicines. Other patients argued
that the active ingredients in many pharmaceutical med-
ications are found in many natural medicines used in
the Amazon, so natural medicines are a more “natural”
way of achieving the same effect. Six patients admitted
stopping the treatment from the health centre at some
point during their schedule to seek a cure in natural
medicines:
The 15 days I didn’t come to the clinic I was taking
natural medicines instead. (007 - patient)
Alternatively, patients take natural medicines alongside
pharmaceutical medicines either in the hope that the
side-effects of the pharmaceutical medicines are made
more manageable, or that they will be cured faster due
to the combined effect of the two types of medicine:
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When I started this treatment here at the clinic… I
had stomach ache and pain and other side-effects. The
shaman told me that I needed to take natural
medicines … So now I am taking both medications.
002 - patient)
I am following the treatment but at the same time I
am taking these natural medicines. I think that this
way I will be cured faster. (013 - patient)
HCPs agreed with this:
Sometimes they tell us that they prefer to take natural
medicines because of the side-effects of the medications
they take that we prescribe … That’s why I think
patients often combine both … to help to deal with the
side-effects. (001 - HCP)
However, natural medicines appeared to be a cause for
concern for many HCPs who expressed worry about
their dangers:
It is dangerous because they don’t know how strong it
could be or dangerous it could be taking those roots or
plants. They could get gastritis or any other illness because
of the effects of the traditional medicines. (008 - HCP)
As a result of the strength of patients’ belief in nat-
ural medicines, HCPs explained that it is more effect-
ive to offer a compromise and to tell patients that they
can take natural medicines, but only once they have
finished their course of pharmaceutical medicines:
We respect their beliefs about the traditional
medications, but we explain to the patients that if they
want to take traditional medications then they can do
it, but after finishing all of the treatment from us at
the health centre. (008 - HCP)
Despite the initial distrust, patients who were nearing
the end of their treatment schedule believed in the effi-
cacy of pharmaceutical medicines. Once patients could
notice an improvement in their condition, they found it
easier to believe in them. Conversely, if patients stop
their treatment from the health centre to take only nat-
ural medicines, they notice a deterioration in their con-
dition and go back to pharmaceutical medicines:
I have a message for all the patients who have MDR-
TB. They shouldn’t take the natural medicine because
it is a lie … and I almost died. (007 - patient)
travelled to a village to live there. There I didn’t take the
medication from the clinic, instead I took natural
treatment based on vegetables and healing plants, but
then I got worse and I came back to the city to follow the
treatment schedule from the health centre. (004 - HCP)
Psychological impact, character and attitudes
Twelve patients described a significant psychological im-
pact due to MDR-TB that begins with diagnosis and
continues for life, which was reinforced by HCPs. Many
patients explained difficulty coming to terms with not
being a “normal” person and being labelled as “ill”:
I am not like a normal person … Everything has
changed. (015 - patient)
The change in identity is compounded by the effect
that MDR-TB and its treatment have on patients’ role
both in their family and society following their diagnosis
due to their inability to work or study and the fear of
passing the illness on to someone else:
I cannot hold her [my daughter]. I want to be with her
as a mother. I want to be able to prepare meals for her
and she wants to be with me. It’s very very hard. (013-
(patient)
Eleven patients also spoke of feeling isolated in their
own homes, which has a significant psychological
impact:
When you have this illness you feel frustrated, like you
are in an enclosed box. (009 - patient)
Stigma and discrimination were also reported by 11
patients and 9 HCPs. This, combined with feelings of
isolation, caused patients to lose their sense of self-
worth:
Yes, it [stigma] affects patients too much. They feel
diminished in society. (016 - HCP)
The importance of a positive patient attitude was
highlighted by 7 patients and 9 HCPs. Both groups
agreed that belief in oneself and a strong desire to be
cured helps a patient overcome the challenges of the
MDR-TB treatment schedule:
I think that it only starts working once you want to get
better. (002 - patient)
HCPs spoke at length about the importance of instil-
ling a positive attitude for keeping patients motivated to
stay on the treatment regimen:
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The patients who stay on the treatment are the ones
who have a positive outlook. Patients who have a
negative attitude are the ones who stop taking the
treatment. (001 - HCP)
Four patients described their source of motivation as
ensuring the safety and future security of their family:
You think about your family when you have this
illness because if you die who is going to support the
family?... You need to finish the treatment. (018 -
patient)
Both patients and HCPs mentioned difficulty man-
aging MDR-TB alongside other comorbidities such as
diabetes, HIV and drug or alcohol dependence. Problems
arise from difficulty with nutrition, polypharmacy, worse
general health and poor engagement with the treatment
program:
Because of my diabetes I need to be careful when I
feed myself. I cannot drink milk or fruit juice or eat
any other fruit like a normal patient. (007 -
patient)
We had some patients who were addicted to drugs. All
8 of those patients left the treatment. I would say that
they did not feel engaged enough to continue with the
treatment. That’s why they left. (012 - HCP)
In Iquitos, there are high rates of alcohol and illicit
drug abuse, especially in areas with high rates of poverty.
HCPs highlighted alcohol abuse as an important barrier
to treatment compliance, as well as cocaine, cannabinoid
and opiate abuse.
External factors affecting outcomes
External factors describe elements that are out of the
control of the patient that influence outcomes, including
socioeconomic, structural and support factors.
Socioeconomic factors
The socioeconomic impact of MDR-TB was mentioned
by all 14 patients and 11 HCPs. Both groups described
how MDR-TB affects patients financially by compromis-
ing their ability to work and the added costs of accessing
treatment. It became evident that both HCPs and pa-
tients agreed that the financial strains of MDR-TB affect
poorer patients most, making it harder for them to
complete their treatment compared to more wealthy
patients. Both the illness itself and the side-effects of
the treatment are disabling and frequently leave pa-
tients too weak to leave their beds. Rest is also an
important part of MDR-TB treatment, so patients are
encouraged not to work during the initial intensive
phase of their treatment by HCPs during the early
stages of their treatment:
I don’t work like I did before. I can’t carry on working
every day. I can’t earn enough money like I used to
when I worked every day. (015 - patient)
Most of the people who live here sell things at the
market. So … the first two months we tell them that
they need to rest and cannot work. (008 - HCP)
As well as the financial implications of being unable to
work, patients must also pay for transport to and from
the clinic every day for their medication:
Well, when I didn’t have this illness, I had money …
Years ago I had a boat, other things and possessions.
Then, because of the illness, I had to sell it all to get
money to pay for the treatment, pay for the transport
and so on … ” (004 - patient)
Seven patients described being unable to take the rec-
ommended rest during their treatment because they
needed to work to provide for their family:
The doctor told me to take a rest for around 30 days. I
couldn’t because of my family. I have to work every
day to support them. That’s why I think my treatment
took 28 months because I had to work, which made it
difficult to follow the treatment. Because if I don’t
work, who is going to support my family? (018 -
patient)
Ten patients described not having enough money to
pay for a healthy diet to ensure good nutrition, or even
to buy 3 meals a day:
I didn’t have enough money to eat and sometimes I
would eat just once, at night. (018 - patient)
The nurse told me that I should eat at least 5 times a
day. I laughed. I asked how could I possibly do that if I
don’t have the money to do that? I wasn’t able to do it
because the financial aspect is so important for
anyone’s treatment. (026 - patient)
Both patients and HCPs agreed that the limited nutri-
tional support from the health centre was helpful. How-
ever, both groups also stressed that it was insufficient,
and that financial support is necessary:
There are cases when the patients need to work and
sometimes, they can only afford to eat once a day,
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which leads to malnutrition … They don’t have the
support of the government... That’s why I say this
system is not working here in my country. (014 - HCP)
If you don’t receive financial support from anyone, it’s
not enough to just receive rice and other products from
the health centre during your treatment. (026 - patient)
Structural factors
Structural factors encompass organisational, regional
and national level issues affecting the care that patients
receive. Access to treatment was highlighted as a barrier
to optimal outcomes not only due to financial reasons,
but also logistical problems:
I also live by the road about 10km from here. I am so
far from the health centre, but I need to come here to
take my medicines so it’s very very difficult for me.
(013 - patient)
We have this problem with flooding in this
neighbourhood, so we can’t visit all the patients or
even a patient can’t come to the health centre. (016 -
HCP)
Working in a resource poor health system, as in Iqui-
tos, presents a number of challenges that can affect out-
comes. Both HCPs and patients described the lack of
specialised personnel in the region leading to long wait-
ing times for appointments:
There is just one doctor who specialises in this illness,
who works at all the clinics and with all the patients. It’s
not easy to get an appointment with him. (002 - HCP)
Furthermore, the environment for consultations and
the general health centre facilities were also raised as
concerns for reasons of privacy and confidentiality and
the storage and maintenance of medication:
I think it would be better if each of us had our own
room, so we could see patients in private, so we
could interact with them and they can feel more
comfortable with sharing sensitive information. (001
- HCP)
Sometimes here at the clinic we don’t have clean
water. Also, my fridge is not working so sometimes I
can’t store certain medications. (014 - HCP)
Both HCPs and patients also spoke of the risk of noso-
comial infection:
The risk is almost constant. It is risky because you
don’t know. Sometimes patients come in without
wearing a mask because they are not diagnosed with
this illness yet. (017 - HCP)
The infrastructure could be improved because the
doctors work in a closed room so it’s easy for the
doctors and nurses to catch the illness. The room
is very small and poorly ventilated so it’s not great
for the doctors’ and nurses’ health. (002 - patient)
Seven patients also mentioned disorganisation of the
local health system as adversely affecting their care:
Well, at the beginning I would say that it [my
care] was not well organised … That’s why I didn’t
take my medication and that’s why I think I have
the same illness again for a second time. (003 -
patient)
Both national and regional politics were cited as bar-
riers to achieving optimal outcomes. Patients and HCPs
stressed that the government must do more to combat
the MDR-TB problem in Peru:
I think that it is down to the government. The
government should invest more money in order to
improve the healthcare system here in Peru. (009 -
patient)
Politics should focus first on the health of the
population. For example, here health should be in first
place, but in Peru I think it is in third place. (017 -
HCP)
Support
Family support was mentioned in 10 patient and 10
HCP interviews as being important. Patients and HCPs
highlighted that a diagnosis of MDR-TB affected the pa-
tients’ families in many ways including the risk of trans-
mission, stigma and discrimination by association and
also the necessity of making sacrifices to provide
support:
It is common for families to have to make sacrifices to
support family members with tuberculosis. (001 -
HCP)
A positive reaction by the family and provision of sup-
port was recognised as being important by both groups:
Definitely. It [family support] is very important
because sometimes when the patient feels sad and
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terrible it’s obvious that they need family support.
Sometimes that can be the reason they don’t finish the
treatment if they don’t have family support... The
family needs to be with the patient during their whole
treatment … to support the patient psychologically or
financially. (021 - HCP)
The only person who stayed with me since I got this
illness is my wife. This is so important because there
are many friends who leave you and don’t want to be
friends any more. But, it is worse when a relative
discriminates you. That makes you feel so bad. (002 -
patient)
Family support was described in many forms includ-
ing: emotional, psychological, financial and nutritional:
First of all, my family helped me psychologically.
My husband, my sisters, my daughters … All my
family helped me. They said, “continue with your
treatment. Don’t leave your treatment.” (007 -
patient)
Six patients highlighted religion as providing them
with psychological support:
When I feel alone, I only trust one person, and that
is God. When I wake up, I think of God. He is the
only one I trust... Thanks to God I am here. (009 -
patient)
Both groups also highlighted the importance of the
quality and nature of the care and support provided by
the HCP team. Ten patients and 9 HCPs stressed that
care provided by the HCP team must be holistic, incorp-
orating a multi-disciplinary team that supports the
patient emotionally and psychologically as well as
medically:
When the patient is diagnosed with this illness, they
receive a complete treatment not just in this area with
the nurses, but they also receive support from other
doctors in other specialties. All the staff support the
patients here. (011 - HCP)
We try to support our patients. We give them some
advice, but it’s not enough. We have here a specialist,
a psychologist; she is here all the time trying to talk to
the patients … Most of the patients with this illness
feel very bad, terrible. (020 - HCP)
Care beyond the health centre and home visits were
also raised as key aspects of the care package:
If we are worried about the patient’s health, we visit
them … and we look for what is happening with that
patient. Maybe he/she cannot travel to the clinic, for
example. We need to know why that patient is not
coming to the health centre. Maybe he/she feels too
weak to come to the health centre and that’s why we
visit them. It is our work. (005 - HCP)
Nine patients also spoke of a pragmatic and individua-
lised treatment plan as being particularly helpful and
they valued involvement in its planning. For example,
when a patient’s job means they cannot access the clinic
during normal working hours:
Because of my work. I used to leave my house early,
early morning so I didn’t have enough time to go to the
health centre every day. That’s why I left the
treatment. Then, after my work, I used to arrive home
late, when the health centre was closed. (026 - patient)
Clinical factors affecting outcomes
Clinical factors refer to aspects of patients’ treatment
that affect their health and ability to finish their treat-
ment schedule.
Side-effects
All patients spoke of side-effects at some point during
their treatment. A range of different side-effects was re-
ported including loss of hearing and vision, nausea, loss
of appetite, weakness, skin discolouration and low mood:
When I take the pills, I think they are strong … And that
causes me dizziness and I lose my vision … Right now, I
can’t see you clearly … I have blurry vision. (004 - patient)
Some patients explained that often the sight of the
pills was enough to invoke nausea and vomiting:
Now I am taking 18 pills every day … When I see the
pills, I want to vomit. (010 - patient)
Other patients reported the side-effects as being disabling,
leaving them bed ridden for the remainder of their day.
After the injection I have to stay in bed almost the
whole day. (002 - patient)
Ten patients and 8 HCPs spoke of strategies to minim-
ise the severity of the side-effects. A common method
was ensuring a meal prior to ingesting the pills:
When they have side-effects sometimes they don’t want
to continue, but when they come here, we explain to
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them that maybe they need to change the way they
take the medications because maybe they could take
them after having breakfast. (011 - HCP)
Other patients found that spreading consumption of
the pills over several hours helped:
Yes, the nurses know about my problems and they help
me … They let me take like 2 and then 2 again after a
break. (010 - patient)
HCP-patient relationship affecting outcomes
The importance of a good, strong and an open HCP-pa-
tient relationship was highlighted by 13 patients and all
11 HCPs. The relationship can act as a foundation upon
which good communication, patient confidence and
trust can be established:
The success of the treatment depends first on the
treatment and then on the relationship you have with
your patient. (011 - HCP)
The relationship between the doctor and the patient is
very important. I think it is the foundation of the
whole treatment and interaction. (017 - HCP)
With some of them I have a good relationship...but
some of them look at you like you’re something weird.
(013 - patient)
Communication
Good communication skills and empathy were cited by
both groups as important skills for HCPs working with
MDR-TB patients:
We must try to be empathetic because we have to be
in our patients’ shoes to know what it is like, what they
are feeling and what they are thinking...We need to
provide good treatment and support, so patients can
feel comfortable enough to finish the treatment. (008 -
HCP)
In addition, HCPs understood that their role is to sup-
port the patient rather than establish a power-imbalance
within the relationship:
It’s not our role to say that “you have to do this” or
“you have to do that”. (014 - HCP)
Twelve patients and 10 HCPs described how good
communication and making patients feel important and
comfortable enough to share their worries or concerns
about their treatment was vital:
I try to give them attention… and try to make them
feel important. I try to call them by their names and
give them the chance to share things. I try to make
them feel confident to share things with me and to
follow the treatment. (011 - HCP)
Researcher: Did you feel comfortable talking to the
nurses about your concerns?
Yes, because I think they understood. (026 - patient)
Many patients mentioned specific nurses whose en-
couragement had helped them during particularly diffi-
cult times:
She [008 (HCP)] supported me when I was going to
leave the treatment. I thought I was going to die and
that’s when she supported me and got me back on the
treatment. I am here thanks to her. (007 - patient)
Furthermore, patients must visit the health centre
every day for their observed treatment and therefore
must feel welcome:
I felt like the clinic was my home. (018 - patient)
We try to make the patient understand that they can
come here any time they want and that they will have
the support of all the staff. (012 - HCP)
If you don’t treat your patients well, they are not going
to come back again. (020 - HCP)
Trust
Trust between HCPs and patients emerged as an im-
portant influencer of outcomes. Patients described trust-
ing the advice of HCPs that was contradictory to the
advice from their peers, while HCPs described trust that
patients would follow their advice when they were not in
the clinic:
Researcher: Does that [advice from peers] ever
disagree with the advice from the doctors?
Yes, it contradicts it. Sometimes they disagree, but I
believe, and I trust the doctors. (007 - patient)
We tell them that we need to follow the treatment
schedule strictly. But we cannot be with the
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patient all the time, so we don’t know if they are
taking natural medicines unless they tell us. (001
- HCP)
Transmission
Eight HCPs spoke of the danger of contracting MDR-TB
themselves. The importance of self-care was evident not
only to protect HCPs themselves, but also to protect
patients:
I try to make sure they understand why I am
wearing the mask. I explain to them that they could
transmit it to me and that’s why I am wearing it
because if I get the illness, who is going to treat
them? (014 - HCP)
A protective mask, worn by most HCPs during consul-
tations with patients, was mentioned several times as a
necessary barrier to communication.
It’s the only barrier. It’s the only barrier, but it’s
necessary. (017 - HCP)
While patients mainly spoke of the risk of transmis-
sion to their family, HCPs stressed the importance of re-
ducing MDR-TB in the population to improve overall
outcomes:
The big problem is that patients sometimes know
they have this illness, but don’t say anything or do
anything and so keep on transmitting the illness to
other people. So that’s the big problem here. (012 -
HCP)
We make sure patients know about the ways they can
pass it on to other people, so we can avoid people passing
this illness on. In that way we are going to reduce the
number of people who have MDR-TB. (021 - HCP)
Discussion
This study identified four principal themes that influ-
ence outcomes for MDR-TB: personal factors, external
factors, clinical factors and the HCP-patient relationship.
Moreover, separate analyses of the patient and HCP
groups produced near identical thematic findings. This
alignment of opinion has not previously been reported
and adds support for a change in MDR-TB management
strategies in Loreto, Peru.
Personal factors
Patients and HCPs agreed that effective education en-
ables the patient to come to terms with their diagnosis,
deal with the side-effects of medication and take respon-
sibility for their own health. The findings of this study
also indicate that improved patient and population
knowledge could facilitate engagement with treatment
by encouraging belief in evidence-based medicine and
dispelling health myths, belief in natural medicines and
stigma. The importance of high standard patient know-
ledge and education is known [5, 20, 27]. However, this
study offers deeper insight into the importance of the
method of delivery. This includes how a variety of infor-
mation sources could be used, most notably the internet
and expert patients, and how information seeking behav-
iour should be encouraged.
Findings revealed a lack of effective patient and popu-
lation level TB and MDR-TB education, which is associ-
ated with poor outcomes [43] and patient loss from
treatment [26]. This study aligns with previous research
showing that despite receiving pre-treatment informa-
tion, being on treatment for a long time and receiving
counselling throughout, many MDR-TB patients con-
tinue to have poor knowledge [20]. Thematic findings of
this study indicate that improved population knowledge
could reduce both the development of resistant strains
and transmission of MDR-TB within the population.
Respondents emphasised the importance of a positive
patient attitude towards MDR-TB treatment, which has
previously been shown to impact patient adherence
[20, 25, 27, 28, 44, 45] and MDR-TB outcomes [5, 46–49].
Patient motivation and attitude are considered diffi-
cult to modify since behavioural change is a complex
and multifactorial process [23]. However, this study
suggests that HCPs can encourage a positive attitude
in patients through effective communication, empathy
and by empowering the people around the patient to
provide quality support.
Interviews provided a novel insight into the cultural
importance of shamans and natural medicines in the
Iquitos and Amazon region. We reported that most pa-
tients will see a shaman before seeing a doctor or nurse.
HCPs indicated that a minority of shamans will refer pa-
tients to doctors, while others will attempt to cure
MDR-TB with natural medicines alone, which are inef-
fective and delay presentation to health centres, and ad-
versely affect patient outcomes [28, 50–54]. Belief in
alternative medicines or negative perceptions of pharma-
ceutical treatment regimens has been associated with a
detrimental impact on adherence [24, 55, 56]. However,
this study has highlighted how deeply ingrained these
beliefs are in the Loreto region and their impact on ad-
herence and help-seeking behaviour.
The dangers of taking both natural and pharmaceut-
ical medicines together were expressed by both patients
and HCPs, which supports previous research [57]. Of
interest, those patients who were near the end of their
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treatment regimen often advocated pharmaceutical med-
icines over natural medicines and would advise others
starting their treatment to avoid natural medicines en-
tirely. If expert patients with MDR-TB were encouraged
to educate new patients it could reduce the negative im-
pact of natural medicines on outcomes. The effective-
ness of peer education has been confirmed in previous
studies investigating other conditions [58, 59].
External factors
The importance of a good support network around the
patient to overcome the influence of structural factors
and the socioeconomic impact of MDR-TB was
identified.
In an area with high rates of poverty and no financial
support available, patients often find themselves locked
in a negative cycle due to the socioeconomic impact of
MDR-TB on them and their families. Both groups in this
study identified 2 options that the financial implications
of MDR-TB commonly leave the patient with: firstly, to
ignore medical advice and continue to work to earn
enough money to provide for themselves and their fam-
ily; secondly, to follow advice and rest, but risk not being
able to provide. Patients who work are unable to rest or
access health centres. However, patients who elect to
rest must survive with less money, and struggle to pay
for transport to access treatment and essential nutrition.
Good nutrition is a vital part of MDR-TB prevention
and treatment. For patients already living in poverty who
cannot work, adequate nutrition is impossible, leading to
longer treatment duration or treatment failure. The so-
cioeconomic impact of TB and MDR-TB adversely influ-
ences adherence [5, 7, 60], ability to work [46, 61] and
outcomes [21]. This study strongly emphasises the need
for financial support for MDR-TB patients in Iquitos. Fi-
nancial support in the form of food vouchers or direct
income replacement has been proven to improve out-
comes in other low-income settings in Nepal [25], South
Africa [62] and elsewhere [25, 30–32]. A recent system-
atic review of all types of financial support for TB pa-
tients concluded that in low and middle income settings
it was paramount to ensure that TB patients received ap-
propriate income replacement to achieve optimal out-
comes, with shorter treatment schedules making it cost
effective [63]. A 2015 study by Wingfield et al. investigat-
ing the impact of incentivised cash transfers and coun-
selling for TB patients from impoverished communities
in Lima, Peru, found that patients responded positively
to the socioeconomic intervention [64]. The findings of
the study aided refinement of the program and it was
hoped that they would provide a template for policy-
and decision-makers in the Peruvian national govern-
ment. This study reiterates the necessity of financial sup-
port for patients with MDR-TB. The framework
proposed by Wingfield et al. should be used to guide im-
plementation of a financial support program.
Patients and HCPs reported structural issues. A num-
ber of patients described difficulties accessing treatment,
including the financial cost and distance to clinic, which
is known to have a detrimental impact on outcomes for
MDR-TB [15, 20, 21, 53, 65]. A resource poor health
system, as in Iquitos, has been shown to adversely affect
patient outcomes [15, 20, 24, 26, 66]. However, a pro-
portion of HCPs argued that pragmatism and ingenuity
allow them to continue to provide a satisfactory level of
care despite a lack of sufficient resources. Both patients
and HCPs described the value of a holistic approach to
care including psychological and emotional support. Pre-
vious literature has described the importance of an indi-
vidualised care strategy engaging and involving the
patient [5, 23].
Patients and HCPs highlighted that issues relating to
the deficit of personnel, funding and adequate and safe
health centre facilities may be attenuated by the support
network around the patient. Support and encouragement
from HCPs, family and peers helps patients maintain a
positive attitude towards their treatment, despite various
challenges. Families invariably have to make sacrifices in
order to support the ill family member and the impact is
proportionally greater in a deprived environment. The
vital support a family can provide includes emotional,
psychological, nutritional and financial. HCP home visits
positively influence outcome [5, 20]. However, this study
has highlighted the important role of education of the
family in empowering them to support the patient ef-
fectively and to prevent health myths and alternative
medicine beliefs of the family from affecting the patient
at home.
Clinical factors
Side-effects are an unfortunate component of the patient
journey through MDR-TB treatment and strategies to
reduce them and help patients deal with them are essen-
tial. All patients described experiencing medication side-
effects, which demonstrates the difficulties of taking
highly toxic drugs. The way patients experience and per-
ceive side-effects determines their ability to tolerate and
continue with treatment. Patient experience of side-ef-
fects of MDR-TB treatment has previously been
described [25, 28, 45] and is associated with poor adher-
ence [20, 44].
The HCP-patient relationship
The benefits of a strong, open and trusting relationship
were highlighted by both patients and HCPs, as were the
hazards of a poor relationship. The relationship acts as
the basis for optimal outcomes through encouraging
communication, patient confidence and trust. Although
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the importance of the HCP-patient relationship is recog-
nised [20, 24, 67], no previous qualitative studies have
carried out separate analyses to compare the two groups,
which has provided a valuable insight into the dynamic
of the relationship and shed light on ways in which a
good relationship can be fostered. Good communication
ensures that patients feel valued, confident and comfort-
able enough to share their worries with HCPs without
fearing judgment. Adherence is essential to cure patients
of MDR-TB, so it is important to ensure that they share
any difficulties they are experiencing so that solutions
can be found. In particular, empathy allows an HCP to
imagine a patient’s situation and struggles while also giv-
ing the patient confidence that the HCP understands
them. This study emphasised the importance of trust in
the HCP-patient relationship, for example, patients must
trust HCPs in order to believe in and follow their advice
about the efficacy of pharmaceutical over natural medi-
cines. Open dialogue and trust between patients and
HCPs about negative perceptions of pharmaceutical
medication has been shown to improve adherence and
patient satisfaction for other conditions [68, 69]. The
role of HCP-patient relationship in MDR-TB manage-
ment must not be underestimated:
The success of the treatment depends first on the
treatment and then on the relationship you have with
your patient. (011 -HCP)
Limitations
All interviews included a translator. One translator was
used throughout the study to ensure consistency. Al-
though translation accuracy checks post-pilot and post
interviews found no obvious discrepancies, understand-
ing and interpretation of the participant voice could
have affected findings [70].
The setting of patient interviews varied based on con-
venience, and their availability. Where interviews oc-
curred in health centres, it is possible that participants
shared a narrative they thought TM, or an HCP would
want to hear, e.g., fewer patient participants admitted
taking natural medicines than was suggested by HCP
participants. Variance of response suggests setting did
not affect the data, but this is not guaranteed.
TM was neutral (not involved with the care of any pa-
tient) and prior to all interviews it was made clear that
nothing the patient shared could affect their care. How-
ever, TM’s possible impact must be considered.
Table 4 HCP themes and subthemes and their influence on MDR-TB outcomes. (Brackets indicate the number of HCPs highlighting
a subtheme in their interview, bold text indicates alignment of opinion between HCPs and patients)
Theme Facilitators to achieving optimal outcomes (frequency out of 11) Barriers to achieving optimal outcomes (frequency out of 11)
Personal Factors − High standard patient knowledge and understanding (10)
− Appreciation of the importance of adherence until
the end of the treatment schedule (8)
− Knowledge of TB and MDR-TB prior to diagnosis (5)
− Targeted education of at-risk groups (4)
− Belief in the efficacy of pharmaceutical medications (8)
- Positive patient attitude, self-responsibility
and desire to be cured (9)
− Psychological resilience (6)
− Information seeking behaviour (8)
− Poor level of understanding of resistance and the
importance of adherence (9)
− Education in non-simple language and not confirming
patient understanding (7)
− Contradictory advice from family or peers (8)
− Lack of belief in health services and/or trust in
alternative medicines (9)
− Patient experience of or fear of stigma, discrimination
or isolation (9)
− Change in patient identity (7)
− Doubt or denial of diagnosis (6)
− Psychological impact of MDR-TB (7)
External Factors − Effective teamwork within the HCP team/health Centre (7)
− Ingenuity and pragmatism in working in a resource
poor setting (4)
− High standard family support (emotional, psychological,
financial and nutritional) (10)
− Holistic approach to care (9)
− Home visits (7)
− Individualised/personalised patient treatment plan (10)
− Resource poor health system (9)
− Lack of political will to improve TB care on a
regional/national government level (4)
− Difficulty accessing treatment due to the financial
impact of transport (9)
− Socioeconomic impact of having MDR-TB (10)
− Patient prioritizing other responsibilities over health (7)
− Poor nutrition (10)
− Impact of illness on patients’ families (6)
Clinical Factors − Observed treatment (7)
− Strategies to reduce side-effects (8)
− Long duration of treatment schedule (8)
− Side-effects of the treatment (11)
− Disabling illness (9)
HCP factors − A good, open and trusting HCP-patient relationship (11)
− Good communication (10)
− The patient feeling valued and comfortable
sharing concerns and worries with the HCP (9)
− Reducing transmission within the population (7)
− Following safety protocols to prevent HCP transmission. (8)
− Poor communication (7)
− Patient experiencing/fearing stigmatisation from HCPs (5)
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Although measures were taken to reduce researcher bias,
for example analytical triangulation with another inde-
pendent researcher, TM’s central position in study de-
sign, data collection and analysis could have influenced
findings. Results are considered relevant to other MDR-
TB patients and their dedicated HCPs in Iquitos, as well
as other resource poor settings in Latin America which
hold similar cultural values. However, findings may not
be reflected in dissimilar settings elsewhere.
Ethical approval did not allow for individual regimens
to be published. However, Additional file 2 contains a
table summary of the Peruvian national guidelines for
the treatment of MDR-TB.
A comparison could have been made between patients
with good adherence to their MDR-TB treatment and
those who were poorly adherent. However, in Iquitos it
became apparent that it would not be possible to contact
MDR-TB patients who were currently poorly adherent
because either they refused to participate, had died, or
the risk of transmission was considered too great.
Conclusions
This study has identified personal, external and clinical
factors that influence MDR-TB outcomes as well as the
importance of the HCP-patient relationship. Patient and
general population knowledge could be improved with
effective education programs using a variety of methods
and information sources including the internet and ex-
pert patients. Improved knowledge, combined with other
personal and external factors, could facilitate engage-
ment with treatment by encouraging belief in evidence-
based medicine and dispelling health myths, belief in
natural medicines and stigma. HCPs should aim to work
with shamans and communities to combat health myths
and promote evidence-based medicine. An open, trust-
ing and strong HCP-patient relationship can positively
influence outcomes by establishing good communica-
tion, trust and a positive patient attitude. A positive atti-
tude enables a patient to overcome adherence barriers
and can also be encouraged by empowering the people
around the patient to provide quality support. The so-
cioeconomic impact of MDR-TB in a low-income setting
is devastating not only to patients, but also their families.
Financial support is necessary for the vast majority of
patients and has been proven both effective and feasible
in other low-income settings.
Although the eradication of MDR-TB is a considerable
challenge, the findings of this study will contribute to-
wards informing positive change towards this goal if they
are considered and prioritised by local and national gov-
ernment. Future research should focus on increasing
population-wide belief in evidence-based medicine and
enhancing patient and population education.
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